Home › Funds › BAKER BROS. ADVISORS LP › TRDA
BAKER BROS. ADVISORS LP position in TRDA
ENTRADA THERAPEUTICS INC · Health Care
BAKER BROS. ADVISORS LP reported holding 5,072,730 shares of TRDA (ENTRADA THERAPEUTICS INC) in its Q2 2026 13F filing — a position valued at US$37.3M, representing 0.20% of its reported portfolio and ranking #42 among its reported holdings. BAKER BROS. ADVISORS LP has disclosed TRDA holdings in 12 of the last 12 reported quarters, going back to Q3 2023.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How BAKER BROS. ADVISORS LP's TRDA position evolved
BAKER BROS. ADVISORS LP first disclosed a stake in TRDA in Q3 2023 at 4,865,819 shares (US$76.9M). The position peaked in Q4 2024 at 4,865,819 shares, worth US$84.1M. Across 12 filings, BAKER BROS. ADVISORS LP increased the stake 1 time(s), trimmed it 0 time(s) and left it unchanged 10 time(s). The most recent filing (Q2 2026) shows 5,072,730 shares valued at US$37.3M.
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2023 | 4.87M | $76.88M | New |
| Q4 2023 | 4.87M | $73.43M | Hold |
| Q1 2024 | 4.87M | $68.95M | Hold |
| Q2 2024 | 4.87M | $69.34M | Hold |
| Q3 2024 | 4.87M | $77.76M | Hold |
| Q4 2024 | 4.87M | $84.13M | Hold |
| Q1 2025 | 4.87M | $43.99M | Hold |
| Q2 2025 | 4.87M | $32.70M | Hold |
| Q3 2025 | 4.87M | $28.22M | Hold |
| Q4 2025 | 5.07M | $52.15M | Add |
| Q1 2026 | 5.07M | $64.02M | Hold |
| Q2 2026 | 5.07M | $37.34M | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About TRDA and 13F data
TRDA (ENTRADA THERAPEUTICS INC) is a Health Care company. 36 other funds we track also report a position in TRDA — the largest reported positions include 5AM Venture Management, LLC (US$29.9M), Merck & Co., Inc. (US$12.8M), MPM BioImpact LLC (US$9.2M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding TRDA
- 5AM Venture Management, LLC 4.06M sh · $29.85M · Q2 2026
- Merck & Co., Inc. 1.74M sh · $12.80M · Q2 2026
- MPM BioImpact LLC 1.25M sh · $9.22M · Q2 2026
- TCG Crossover Management, LLC 1.06M sh · $7.80M · Q2 2026
- StepStone Group LP 761.28K sh · $5.60M · Q2 2026
- Lynx1 Capital Management LP 178.61K sh · $1.31M · Q2 2026
More on BAKER BROS. ADVISORS LP
FAQ
How long has BAKER BROS. ADVISORS LP held TRDA?
BAKER BROS. ADVISORS LP has disclosed TRDA holdings in 12 of the last 12 reported quarters, going back to Q3 2023.
What is BAKER BROS. ADVISORS LP's current position in TRDA?
As of Q2 2026, BAKER BROS. ADVISORS LP holds 5.07M shares of TRDA (ENTRADA THERAPEUTICS INC), valued at $37.34M, representing 0.20% of its reported portfolio and ranking #42.
Has BAKER BROS. ADVISORS LP been buying or selling TRDA?
In the latest 13F filing (Q2 2026), BAKER BROS. ADVISORS LP held unchanged its position in TRDA. The position peaked in Q4 2024 at 4.87M shares.
Which other funds hold TRDA?
Other major institutional holders of TRDA include 5AM Venture Management, LLC, Merck & Co., Inc., MPM BioImpact LLC, among 36 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.